Metsera started by Guggenheim at buy on obesity drug opportunity
Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates. The bank highlighted Metsera's (NASDAQ:MTSR) long-acting GLP-1RA asset ...
Business Insider23d
Guggenheim First Quarter 2025 High Yield and Bank Loan Outlook: Reframing Tight Spreads in Leveraged Credit
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Guggenheim Investments, the global asset management and investment advisory business of Guggenheim Partners, today released its first quarter High Yield ...
Guggenheim Lowers Venture Global (NYSE:VG) Price Target to $20.00
Venture Global (NYSE:VG – Get Free Report) had its target price cut by equities researchers at Guggenheim from $27.00 to ...
Arvinas Holding Company (ARVN) Receives a Buy from Guggenheim
Guggenheim analyst Michael Schmidt maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) yesterday and set a price target ...
The Bakersfield Californian24d
Guggenheim First Quarter 2025 High Yield and Bank Loan Outlook: Reframing Tight Spreads in ...
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Guggenheim Investments, the global asset management and investment advisory business of Guggenheim Partners, today released its first quarter High Yield ...